Biohaven Pharmaceuticals (NYSE:BHVN) +7.8% after-hours on news the Food and Drug Administration approved its Nurtec ODT (rimegepant) for the acute treatment of migraine in adults.
The company says a single 75 mg oral dose of the
pill can provide fast pain relief, return patients to normal function
within one hour and deliver sustained efficacy that lasts up to 48 hours
for many patients.
Biohaven hopes rimegepant’s oral use and its dual
application will help it stand out from rival drugs, as most other
calcitonin gene-related peptide inhibitors approved for migraine
prevention are administered by injections.
https://seekingalpha.com/news/3546890-biohaven-pharma-wins-fda-approval-for-migraine-treatment
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.